Amycretin
Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.[1][2][3][4][5]
Clinical trials
[edit]On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin showed participants lost 13.1% of their weight after 12 weeks. For comparison, clinical trials for the older drug, Wegovy, which was also developed by Novo Nordisk, indicated weight loss of 6% after 12 weeks and 15% after 68 weeks.[6]
In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Ttreatment duration was up to 36 weeks. The trial legs were:[7]
- combined single ascending dose
- multiple ascending dose
- dose-response trial
The primary endpoint was emergent adverse events. The safety profile was consistent with incretin-based therapies. The most common adverse events were gastrointestinal of mild to moderate severity.[7]
Adherent subjects began with a mean body weight of 92.7 kg. Aamycretin subjects achieved an estimated body weight loss of:[7]
- 9.7% on 1.25mg (20 weeks)
- 16.2% on 5mg (28 weeks)
- 22.0% on 20mg (36 weeks).
Subjects in the placebo arms experienced an estimated 1.9%, 2.3% and 2.0% weight gain.[7]
Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.[6]
References
[edit]- ^ Melson, Eka; Ashraf, Uzma; Papamargaritis, Dimitris; Davies, Melanie J. (1 February 2024). "What is the pipeline for future medications for obesity?". International Journal of Obesity: 1–19. doi:10.1038/s41366-024-01473-y. ISSN 1476-5497.
- ^ Linnane, Ciara. "Viking Therapeutics faces higher bar for oral weight-loss drug". MarketWatch. Retrieved 11 March 2024.
- ^ Jamaluddin, Aqfan; Gorvin, Caroline M (21 March 2023). "RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis". Journal of Molecular Endocrinology. 70 (4). Bioscientifica. doi:10.1530/jme-23-0014. ISSN 0952-5041. PMC 10160555.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663. ISSN 1467-7881.
- ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (March 2024). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. 25 (3). doi:10.1111/obr.13663.
- ^ a b ""Novo valuation surpasses Tesla on experimental obesity drug data"". Reuters. 7 March 2024. Retrieved 13 March 2024.
- ^ a b c d "Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity". Novo Nordisk. 24 January 2025. Retrieved 29 January 2025.